Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis by D. V. Garbuzenko

“…Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.Conclusion. …”
Get full text

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment o... by Yan Gong, James Rogers, Christian Friedrich, Sanjay Patel, Alexander Staab, Jorge Luiz Gross, Daniel Polhamus, William Gillespie, Brigitta Ursula Monz, Silke Retlich

“…Comparison of two oral dipeptidyl peptidase (DPP)-4 inhibitors, sitagliptin and linagliptin, for type 2 diabetes mellitus (T2DM) treatment was used as an example.Design Systematic review with MBMA.Data sources MEDLINE, EMBASE, http://www.ClinicalTrials.gov, Cochrane review of DPP-4 inhibitors for T2DM, sitagliptin trials on Food and Drug Administration website to December 2011 and linagliptin data from the manufacturer.Eligibility criteria for selecting studies Double-blind, randomised controlled clinical trials, ≥12 weeks’ duration, that analysed sitagliptin or linagliptin efficacies as changes in glycated haemoglobin (HbA1c) levels, in adults with T2DM and HbA1c >7%, irrespective of background medication.Model development and application A Bayesian model was fitted (Markov Chain Monte Carlo method). …”
Get full text

From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases by Qing Zhao, Linxin Wei, Youxin Chen

“…This review summarizes the application strategies and delivery methods of CRISPR/Cas, discusses recent progress in CRISPR/Cas-based disease models and therapies, and provides an overview of the landscape of clinical trials. Current obstacles and future directions regarding the bench-to-bedside transition are also discussed.…”
Get full text

Randomised controlled trial of topical kanuka honey for the treatment of rosacea by James Fingleton, Mark Weatherall, Richard Beasley, Irene Braithwaite, Janwillem Kocks, Mark Holliday, Andrew Corin, Colin Helm, Davitt Sheahan, Barney Montgomery, Judith Riley, Anna Hunt, Christopher Tofield

“…The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control.Conclusions Honevo is an effective treatment for rosacea.Trial registration number This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.…”
Get full text

Artificial intelligence-based video monitoring of movement disorders in the elderly: a review on current and future landscapes by Kye Won Park, Maryam S Mirian, Martin J McKeown

“…The AI-based video monitoring systems offer improved efficiency and objectivity in remote patient monitoring, enabling real-time analysis of data, more uniform outcomes and augmented support for clinical trials. However, challenges, such as video quality, privacy compliance and noisy training labels, during development need to be addressed. …”
Get full text

Current and future therapeutic options for chronic hepatitis D virus infection by Mariantonietta Pisaturo, Antonio Russo, Pierantonio Grimaldi, Salvatore Martini, Nicola Coppola

“…PegIFNα, for which there are more data, appears to be an excellent combination regimen, if not contraindicated, both for Bulevirtide (BLV), data supported by important clinical trials and real-world studies, and probably for lonarfanib, although in the latter case the results are not yet definitive as the studies are fewer. …”
Get full text

Effectiveness of Prolotherapy for Chronic Musculoskeletal Conditions by Saurabh Agarwal, Abhishek Nagaich, Nikhil Jain, Arvind Kumar Shah

“…The efficacy of prolotherapy for different musculoskeletal conditions with different injections is different, and the precise mechanism of prolotherapy effect is still not clear, so further studies and clinical trials are recommended.…”
Get full text

Inflammatory Bowel Disease and Statins by V. V. Genkel, I. I. Shaposhnik

“…However, well-planned randomised clinical trials are needed to evaluate the effects of statins in IBD.…”
Get full text

Linezolid and serotonin syndrome by Haytham A. Wali

“…Assessments of the pharmacological mechanisms, large-scale clinical trials, and cohort studies are essential to elucidate risk factors and outcomes. …”
Get full text

Belzutifan for the treatment of renal cell carcinoma by Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi

“…Belzutifan has demonstrated activity in clinical trials as a front- and later-line therapy, and in combination with tyrosine kinase inhibitors. …”
Get full text

Intestinal microbiome as effective regulator of enteral and central nervous system activity by V. T. Ivashkin, K. V. Ivashkin

“…Accumulated data change the current concept on human microbiome and its potential, however further clinical trials required.…”
Get full text

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care by Drew M Pardoll, Suzanne L Topalian

“…Neoadjuvant (presurgical) anti-programmed cell death protein-1 (PD-1)-based immunotherapy as a new approach to cancer treatment has been developing on an accelerated trajectory since the seminal clinical trial results from studies in lung cancer and melanoma were published in 2018. …”
Get full text

Diagnostic accuracy of calculated serum osmolarity to predict dehydration in older people: adding value to pathology laboratory reports by Lee Shepstone, John F Potter, Lee Hooper, Asmaa Abdelhamid, Amy Jennings, Paul R Hunter, W Garry John, Neil P Walsh, Adam Ali, Diane K Bunn, Susan Kerry, Gregor Lindner, Carmen A Pfortmueller, Fredrik Sjöstrand, Susan J Fairweather-Tait

“…Given costs and prevalence of dehydration in older people we suggest use of the best formula by pathology laboratories using a cutpoint of 295 mOsm/L (sensitivity 85%, specificity 59%), to report dehydration risk opportunistically when serum glucose, urea and electrolytes are measured for other reasons in older adults.Trial registration numbers: DRIE: Research Register for Social Care, 122273; NU-AGE: ClinicalTrials.gov NCT01754012.…”
Get full text

Adjuvants for peptide-based cancer vaccines by Willem W Overwijk, Hiep Khong

“…One reason for this difference may be the use of potent, effective vaccine adjuvants in animal models, vs. the use of safe, but very weak, vaccine adjuvants in clinical trials. As vaccine adjuvants dictate the type and magnitude of the T cell response after vaccination, it is critical to understand how they work to design safe, but also effective, cancer vaccines for clinical use. …”
Get full text

Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases by A. A. Sheptulin, S. S. Kardasheva, A. A. Kurbatova

“…Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.…”
Get full text

Advances in sodium-glucose transporter protein 2 inhibitors and tumors by Jiaqi Wang, Wenyong Yang

“…The aim of this article is to provide a comprehensive understanding of the research progress of SGLT2i in different tumors by integrating the latest studies and to encourage further exploration of SGLT2i therapies in clinical trials. This could pave the way for more effective management strategies and improved outcomes for tumor patients.…”
Get full text

Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review by Marco Ruella, Guido Ghilardi, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, Lena E. Winestone, Alfred L. Garfall

“…We also review the representation of age, racial, and ethnic groups in key CAR-T clinical trials. We focus on B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin’s lymphoma, and multiple myeloma.…”
Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

“…This trial was registered at ClinicalTrials.gov (NCT04396457) and the Japan Registry of Clinical Trials (jRCTs041200012).…”
Get full text

Assessment of Bowel Preparation Using Low-Volume Sulphate-Based Preparations in Comparison with Macrogols: A Multicenter, Randomized, Comparative Clinical Study of the 3rd Phase by Evgeny D. Fedorov, Viktor V. Veselov, Sergey V. Kashin, Ekaterina V. Tikhomirova, Alexey V. Veselov, Dmitry V. Zavyalov, Anne Kornowski, Tatyana Gorskaya, Magali Volteau, Thierry Ponchon

“…Despite the higher incidence of nausea in the OSS group, the patients showed significantly higher compliance with the OSS mode as compared to that of Macrogol.This study is registered with the ClinicalTrials.gov Registry of Clinical Trials, No. NCT02321462.…”
Get full text

Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections by Beata Zalewska-Piątek, Michalina Nagórka

“…PT demonstrates significant potential in treating chronic and recurrent UTIs, also including catheter-associated infection by reducing bacterial biofilms, delaying catheter blockage, and enhancing antibiotic efficacy when used in combination. Clinical trials and case studies have reported high rates of bacterial eradication and symptom improvement with minimal side effects. …”
Get full text